Quest Diagnostics Inc. (DGX): Price and Financial Metrics

Quest Diagnostics Inc. (DGX): $137.29

0.83 (+0.61%)

POWR Rating

Component Grades














  • DGX scores best on the Quality dimension, with a Quality rank ahead of 93.54% of US stocks.
  • The strongest trend for DGX is in Quality, which has been heading up over the past 179 days.
  • DGX's current lowest rank is in the Sentiment metric (where it is better than 16.91% of US stocks).

DGX Stock Summary

  • Quest Diagnostics Inc's market capitalization of $16,889,711,486 is ahead of 86.04% of US-listed equities.
  • With a price/earnings ratio of 8.47, Quest Diagnostics Inc P/E ratio is greater than that of about only 18.85% of stocks in our set with positive earnings.
  • Quest Diagnostics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 14.1%, greater than the shareholder yield of 88% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Quest Diagnostics Inc are SNX, IEX, ACGL, FIVE, and ALLE.
  • DGX's SEC filings can be seen here. And to visit Quest Diagnostics Inc's official web site, go to

DGX Valuation Summary

  • In comparison to the median Healthcare stock, DGX's EV/EBIT ratio is 75.09% lower, now standing at 7.3.
  • Over the past 243 months, DGX's price/sales ratio has gone down 0.
  • Over the past 243 months, DGX's price/sales ratio has gone down 0.

Below are key valuation metrics over time for DGX.

Stock Date P/S P/B P/E EV/EBIT
DGX 2021-08-31 1.7 3.2 8.3 7.3
DGX 2021-08-30 1.7 3.1 8.2 7.3
DGX 2021-08-27 1.6 3.1 8.1 7.2
DGX 2021-08-26 1.7 3.1 8.1 7.2
DGX 2021-08-25 1.7 3.1 8.1 7.2
DGX 2021-08-24 1.7 3.1 8.1 7.2

DGX Growth Metrics

    The 5 year net income to common stockholders growth rate now stands at 5.73%.
  • Its 5 year cash and equivalents growth rate is now at 167.19%.
  • Its 5 year net cashflow from operations growth rate is now at 34.85%.
DGX's revenue has moved up $3,250,000,000 over the prior 34 months.

The table below shows DGX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 10,788 2,233 1,995
2021-09-30 11,046 2,293 2,184
2021-06-30 11,058 2,594 2,247
2021-03-31 10,335 2,489 1,801
2020-12-31 9,437 2,005 1,431
2020-09-30 8,361 1,812 1,105

DGX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DGX has a Quality Grade of B, ranking ahead of 93.32% of graded US stocks.
  • DGX's asset turnover comes in at 0.812 -- ranking 31st of 81 Healthcare stocks.
  • SSY, LH, and BIOC are the stocks whose asset turnover ratios are most correlated with DGX.

The table below shows DGX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.812 0.403 0.404
2021-06-30 0.805 0.412 0.417
2021-03-31 0.750 0.404 0.340
2020-12-31 0.709 0.385 0.277
2020-09-30 0.643 0.362 0.221
2020-06-30 0.604 0.334 0.162

DGX Price Target

For more insight on analysts targets of DGX, see our DGX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $157.67 Average Broker Recommendation 1.56 (Moderate Buy)

DGX Stock Price Chart Interactive Chart >

Price chart for DGX

DGX Price/Volume Stats

Current price $137.29 52-week high $174.16
Prev. close $136.46 52-week low $125.33
Day low $135.48 Volume 325,159
Day high $138.40 Avg. volume 1,169,354
50-day MA $136.35 Dividend yield 1.93%
200-day MA $143.36 Market Cap 16.11B

Quest Diagnostics Inc. (DGX) Company Bio

Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United StatesPuerto RicoMexico, and Brazil.  Quest also maintains collaborative agreements with various hospitals and clinics across the globe. (Source:Wikipedia)

DGX Latest News Stream

Event/Time News Detail
Loading, please wait...

DGX Latest Social Stream

Loading social stream, please wait...

View Full DGX Social Stream

Latest DGX News From Around the Web

Below are the latest news stories about Quest Diagnostics Inc that investors may wish to consider to help them evaluate DGX as an investment opportunity.

Newark Mayor Baraka Recognizes Choose Healthy Life for Its Major Role in the Success of the City’s COVID-19 Vaccination Effort

Newark named the nation’s first Choose Healthy City Mayor Declares Sunday, Feb. 27th as Choose Healthy Life Day

Yahoo | February 25, 2022

Honoring Black History Month with Action

Black History Month is a time to reflect on—and express our collective gratitude for—the contributions and legacy of Black Americans to U.S. history and society. From activists and civil rights lea...

Yahoo | February 24, 2022

Analyst: Quest Diagnostics Stock Has a Tough Road Ahead

UBS downgraded Quest Diagnostics stock to "neutral" from "buy"

Schaeffers Investment Research | February 23, 2022

UBS downgrades Quest Diagnostics, sees company at risk of missing earnings targets

UBS said Quest''s 2023 earnings guidance may be too aggressive given the company''s rising costs.

CNBC | February 23, 2022

Quest Diagnostics cut to neutral at UBS on risk of missing FY 2023 earnings target (DGX)

UBS has downgraded Quest Diagnostics (DGX) from buy to neutral on fears the company wont be able to meet its own earnings target in 2023.

Seeking Alpha | February 23, 2022

Read More 'DGX' Stories Here

DGX Price Returns

1-mo N/A
3-mo 0.81%
6-mo -19.91%
1-year 5.15%
3-year 43.19%
5-year 36.48%
YTD -19.91%
2021 47.86%
2020 14.11%
2019 31.13%
2018 -13.84%
2017 9.16%

DGX Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full DGX Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6046 seconds.